Global IDMO leverage Cellares operates a global network of automated Smart Factories (US, Netherlands, Japan) enabling scalable, end-to-end cell therapy manufacturing. Sales opportunities exist in expanding capacity for sponsors seeking commercial-scale, compliant production across regions without building in-house facilities.

Automation advantage With Cell Shuttle and Cell Q delivering high automation, 100% success in automated processes, and up to 10x batch throughput versus conventional CDMOs, pitch the value of reduced manufacturing risk, faster time-to-market, and cost-per-dose improvements to potential partners and trial sponsors.

Clinical validation FDA IND amendments enabling active clinical manufacturing and first patient dosing across multiple therapeutic areas strengthens credibility. Target biotech and pharma sponsors ambitious on clinical programs who need reliable, compliant manufacturing for trials and early commercial use.

Scale-ready partnerships Recent strategic financings and large-scale manufacturing agreements (e.g., Bristol Myers Squibb and Cabaletta Bio) signal readiness for multi-market, long-term commercialization. Opportunities exist to offer expanded capacity, regional supply security, and joint go-to-market models with growing cell therapy programs.

Industry 4.0 value prop Integrated development and manufacturing with Industry 4.0 workflows and robust tech stack (SAP, MuleSoft, ISO 9001, etc.) enable standardized, auditable, and transparent production. Sell the efficiency, governance, and data-enabled decision making to sponsors seeking quality, compliance, and traceability at scale.